Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure (SAFE-LAAC)
-
- STATUS
- Recruiting
-
- End date
- Jun 23, 2027
-
- participants needed
- 200
-
- sponsor
- Institute of Cardiology, Warsaw, Poland
Summary
SAFE-LAAC Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device
Description
- Background
Transcatheter left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation in preventing cardioembolic strokes associated with atrial fibrillation. However, an optimal antithrombotic treatment regimen following successful LAAC remains an unresolved issue. The scope and duration of antiplatelet treatment following LAAC are of paramount importance as they may significantly contribute to post-procedural as well as long-term procedural safety and efficacy.
- Objective
SAFE-LAAC Trial has been designed as a comparative health effectiveness study with the following aims:
- compare the safety and efficacy of 30 days vs. 6 months of dual antiplatelet therapy following LAAC with Amplatzer or WATCHMAN device (randomized comparison)
- compare safety and efficacy of stopping all antithrombotic and antiplatelet agents 6 months after LAAC vs. long-term treatment with a single antiplatelet agent (nonrandomized comparison)
Patient population:
Patients (n=200) after successful LAAC with Amplatzer or WATCHMAN device.
- Perspective
Results of this pilot trial will provide: 1. data to aid practitioners and guideline writers recommend the most optimal antithrombotic treatment after LAAC, and 2. data to support power calculations for designing future randomized trials.
- Methodology
SAFE LAAC has been designed as a multicenter (planned contribution of 7 centers in Poland), open-label, comparative health effectiveness trial with central, independent adjudication of events comprising the primary end-point. The first part of the trial is randomized and after 6 months of follow-up continues for another 12 months as a non-randomized study.
- Timeline
The duration of the trial has been planned for 5 years. The enrollment phase has been planned for 3 years.
Details
| Condition | Atrial Fibrillation |
|---|---|
| Treatment | short postimplantation dual antiplatelet therapy, extended postimplantation dual antiplatelet therapy, long-term treatment with a single antiplatelet agent, 6 months treatment with a single antiplatelet agent |
| Clinical Study Identifier | NCT03445949 |
| Sponsor | Institute of Cardiology, Warsaw, Poland |
| Last Modified on | 4 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer